Alessandro Riva
Chief Executive Officer at TRANSGENE
Net worth: 852 375 $ as of 2024-03-30
Profile
Alessandro Riva is the founder of Breast Cancer International Research Group Ltd., Cancer International Research Group.
He currently holds the position of Chairman & Chief Executive Officer at Transgene SA, Chief Executive Officer at Intima Bioscience, Inc., Independent Non-Executive Director at BeiGene Ltd., and Independent Director at Century Therapeutics, Inc. Previously, he served as the Chief Executive Officer-Innovation Business at Glenmark Pharmaceuticals Ltd., Director at Ichnos Sciences, Inc., Director at Century Therapeutics, Inc., Executive VP-Oncology Therapeutics at Gilead Sciences, Inc., President at Novartis Oncology, Inc., and VP, Head-Oncology Development & Medical Affairs at Novartis AG.
He also held the position of EVP, Head-Oncology Development & Medical Affairs at Novartis Pharmaceuticals Corp.
Dr. Riva obtained his undergraduate and doctorate degrees from the University of Milan.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BEIGENE LTD
0.01% | 2023-06-14 | 70,148 ( 0.01% ) | 852 375 $ | 2024-03-30 |
| 2023-06-26 | 0 ( -.--% ) | - $ | 2024-03-30 |
Alessandro Riva active positions
| Companies | Position | Start |
|---|---|---|
| BEIGENE, LTD. | Director/Board Member | 2022-01-31 |
| CENTURY THERAPEUTICS, INC. | Director/Board Member | 2021-04-30 |
| TRANSGENE | Chief Executive Officer | 2023-05-31 |
Intima Bioscience, Inc.
 Intima Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Intima Bioscience, Inc. is a bioscience company that is advancing checkpoint cell therapy for solid tumors with curative intent. The private company is based in New York, NY. The company combines the use of patients' own immune cells with immune checkpoint targeting. Intima is currently running a phase 1/2 clinical study of its checkpoint cell therapy, which targets the immune checkpoint cish in patients with gastrointestinal and colon cancers. Alessandro Riva has been the CEO of the company since 2021. | Chief Executive Officer | 2021-08-31 |
Former positions of Alessandro Riva
| Companies | Position | End |
|---|---|---|
Ichnos Sciences, Inc.
 Ichnos Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ichnos Sciences, Inc. operates as a biotechnology company. It provides curative therapies that extend human life. The company was founded in 2019 and is headquartered in Paramus, NJ. | Chief Executive Officer | 2021-05-20 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 2019-03-05 |
| NOVARTIS AG | Corporate Officer/Principal | 2016-11-30 |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | President | 2015-12-31 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 2015-12-31 |
Training of Alessandro Riva
| University of Milan | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 6 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| TRANSGENE | Health Technology |
| NOVARTIS AG | Health Technology |
| GLENMARK PHARMACEUTICALS LIMITED | Health Technology |
| BEIGENE, LTD. | Health Technology |
| CENTURY THERAPEUTICS, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
| Breast Cancer International Research Group Ltd. | |
Intima Bioscience, Inc.
Intima Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Intima Bioscience, Inc. is a bioscience company that is advancing checkpoint cell therapy for solid tumors with curative intent. The private company is based in New York, NY. The company combines the use of patients' own immune cells with immune checkpoint targeting. Intima is currently running a phase 1/2 clinical study of its checkpoint cell therapy, which targets the immune checkpoint cish in patients with gastrointestinal and colon cancers. Alessandro Riva has been the CEO of the company since 2021. | Health Technology |
Ichnos Sciences, Inc.
Ichnos Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ichnos Sciences, Inc. operates as a biotechnology company. It provides curative therapies that extend human life. The company was founded in 2019 and is headquartered in Paramus, NJ. | Commercial Services |
Century Therapeutics, Inc. /Old/
 Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Health Technology |
| Cancer International Research Group |
- Stock Market
- Insiders
- Alessandro Riva
